vimarsana.com

Page 104 - பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

Can Infants Catch Cancer from their Mothers at Birth?

Can Infants Catch Cancer from their Mothers at Birth? Published January 7th, 2021 - 12:02 GMT (Shutterstock/ File Photo) In extremely rare instances, newborns can contract cancer from their pregnant moms during delivery, a new case report suggests. Two boys, a 23-month-old and a 6-year-old, developed lung cancers that proved an exact genetic match to cervical cancers within their mothers at the time of birth, Japanese researchers report. It appears that the boys breathed in cancer cells from their mothers tumors while they were being born, cancer experts say. In our cases, we think that tumors arose from mother-to-infant vaginal transmission through aspiration of tumor-contaminated vaginal fluids during birth, said lead researcher Dr. Ayumu Arakawa, a pediatric oncologist with the National Cancer Center Hospital in Tokyo.

The Link Between Gut Health and Breast Cancer

The Link Between Gut Health and Breast Cancer By Amanda Gardner The tens of trillions of microorganisms living and working in your gut called your microbiome may hold clues to preventing, treating, and surviving many diseases, including breast cancer. “The microbiome shows important differences in people with breast cancer and people without breast cancer,” says Alice Police, MD, Westchester regional director of breast surgery at Northwell Health Cancer Institute in New York. But it’s unclear whether these changes came before breast cancer or the other way around. Experts also don’t know if there’s a way to change someone’s microbiome to improve breast cancer outcomes or even prevent the disease, but that’s the hope.

MD Anderson and Xencor enter strategic collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of patients with cancer

MD Anderson and Xencor enter strategic collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of patients with cancer This collaboration joins Xencor’s innovative XmAb ® technology and protein engineering expertise to create bispecific antibodies with MD Anderson’s expertise in the research and discovery of novel therapeutic antibodies, including the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform, part of MD Anderson’s Therapeutics Discovery division. “Xencor’s modular antibody engineering platform enables the rapid generation of XmAb ® bispecific antibodies, and our research collaboration with MD Anderson will further expand the use of our technology to explore novel therapeutic targets, which could result in the creation of new therapies for patients with cancer,” said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.